Financial Projections - The company expects a net profit of between 190 million and 235 million CNY for 2025, representing a year-on-year increase of 22.28% to 51.24%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 128.5 million and 164 million CNY, reflecting a growth of 38.97% to 77.37% compared to the previous year[5] - The expected operating revenue for 2025 is between 1.08 billion and 1.2 billion CNY, up from 843.48 million CNY in the previous year[5] Market Recovery - The significant increase in revenue is attributed to the recovery of the North American market, with the impact of inventory destocking in the U.S. having dissipated[7] Audit and Evaluation - The financial data presented is based on preliminary estimates by the company's finance department and has not yet been audited by an external accounting firm[6] - The final performance data will be subject to professional evaluation and audit, with specific figures to be disclosed in the company's 2025 annual report[8] - The company has communicated with the auditing firm regarding the performance forecast, and there are no significant discrepancies between the two parties[6] Investor Advisory - The company advises investors to make cautious decisions and be aware of investment risks due to the preliminary nature of the performance forecast[8] Performance Forecast Period - The performance forecast period is from January 1, 2025, to December 31, 2025[3] Announcement Date - The board of directors announced the performance forecast on January 19, 2026[10]

具体来看，合计持有公司4.999%股份的股东能金有限公司及其一致行动人广州市金垣创业投资合伙企 业（有限合伙）计划在自减持计划公告之日起15个交易日后的3个月内以集中竞价方式或大宗交易方式 减持公司股份累计不超过220.8万股，占公司总股本比例2.49%（总股本已剔除公司回购专用账户中的股 份数量）。 此外，合计持有公司15.88%股份的股东珠海合晅投资中心（有限合伙）及其一致行动人上海盛旻创业 投资合伙企业（有限合伙）计划在自减持计划公告之日起15个交易日后的3个月内以集中竞价方式或大 宗交易方式减持本公司股份累计不超过220.8万股，占公司总股本比例2.49%。 （文章来源：北京商报） 北京商报讯1月16日晚间，瑞迈特（301367）发布公告称，多名股东拟合计减持不超过4.98%公司股 份。 ...

2、合计持有本公司股份14,228,601股（占本公司总股本比例15.88%）的股东珠海合晅投资中心（有限 合伙）及其一致行动人上海盛旻创业投资合伙企业（有限合伙）计划在自本减持计划公告之日起15个交 易日后的3个月内以集中竞价方式或大宗交易方式减持本公司股份累计不超过2,208,000股，占本公司总 股本比例2.49%。 格隆汇1月16日丨瑞迈特(301367.SZ)公布，1、合计持有本公司股份4,479,120股（占本公司总股本比例 4.9990%）的股东能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限合伙）计划在自本 减持计划公告之日起15个交易日后的3个月内以集中竞价方式或大宗交易方式减持本公司股份累计不超 过2,208,000股，占本公司总股本比例2.49%（总股本已剔除公司回购专用账户中的股份数量）。 ...

股东珠海合晅投资中心(有限合伙)及其一致行动人上海盛旻创业投资合伙企业(有限合伙)计划在自本减 持计划公告之日起15个交易日后的3个月内以集中竞价方式或大宗交易方式减持公司股份累计不超过 220.8万股，占公司总股本比例2.49%。 瑞迈特（301367）(301367.SZ)发布公告，股东能金有限公司及其一致行动人广州市金垣创业投资合伙 企业(有限合伙)计划在自本减持计划公告之日起15个交易日后的3个月内以集中竞价方式或大宗交易方 式减持公司股份累计不超过220.8万股，占公司总股本比例2.49%。 ...

智通财经APP讯，瑞迈特(301367.SZ)发布公告，股东能金有限公司及其一致行动人广州市金垣创业投资 合伙企业(有限合伙)计划在自本减持计划公告之日起15个交易日后的3个月内以集中竞价方式或大宗交 易方式减持公司股份累计不超过220.8万股，占公司总股本比例2.49%。 股东珠海合晅投资中心(有限合伙)及其一致行动人上海盛旻创业投资合伙企业(有限合伙)计划在自本减 持计划公告之日起15个交易日后的3个月内以集中竞价方式或大宗交易方式减持公司股份累计不超过 220.8万股，占公司总股本比例2.49%。 ...

21智讯1月16日电，瑞迈特公告，合计持有公司股份4,479,120股（占公司总股本比例4.9990%）的股东 能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限合伙）计划在自本减持计划公告之日 起15个交易日后的3个月内以集中竞价方式或大宗交易方式减持公司股份累计不超过2,208,000股，占公 司总股本比例2.49%；合计持有公司股份14,228,601股（占公司总股本比例15.88%）的股东珠海合晅投 资中心（有限合伙）及其一致行动人上海盛旻创业投资合伙企业（有限合伙）计划在相同期间内以集中 竞价方式或大宗交易方式减持公司股份累计不超过2,208,000股，占公司总股本比例2.49%。本次减持原 因为自身资金安排需求，股份来源为公司首次公开发行股票上市前持有的股份，减持价格将根据二级市 场实际交易价格确定。 ...

瑞迈特公告，能金有限公司及一致行动人广州市金垣创业投资合伙企业（有限合伙）持有447.91万股， 占4.9990%，拟15个交易日后3个月内以集中竞价或大宗交易减持不超220.8万股，占2.49%；珠海合晅投 资中心（有限合伙）及一致行动人上海盛旻创业投资合伙企业（有限合伙）持有1422.86万股，占 15.88%，同期减持不超220.8万股，占2.49%。 ...

证券代码：301367 证券简称：瑞迈特 公告编号：2026-003 北京瑞迈特医疗科技股份有限公司 关于特定股东、持股5%以上股东及其一致行动人减 持股份的预披露公告 公司股东能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限 合伙）、珠海合晅投资中心（有限合伙）及其一致行动人上海盛旻创业投资合伙 企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 北京瑞迈特医疗科技股份有限公司（以下简称"公司"）于近日收到能金有 限公司（以下简称"能金公司"）及其一致行动人广州市金垣创业投资合伙企业 （有限合伙）（以下简称"广州金垣"）、珠海合晅投资中心（有限合伙）（以 1 下简称"合晅投资"）及其一致行动人上海盛旻创业投资合伙企业（有限合伙） （以下简称"盛旻创投"）出具的《关于股份减持计划的告知函》。现将有关情 况说明如下： 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、合计持有本公司股份 4,479,120 股（占本公司总股本比例 4.9990%）的股 东能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限合伙）计划 ...

Core Viewpoint - The stock price of Ruimait has experienced fluctuations, with a recent decline of 2.00% and a total market capitalization of 8.107 billion yuan. The company has seen a net outflow of funds, indicating potential investor caution [1]. Group 1: Stock Performance - Ruimait's stock has increased by 5.57% year-to-date, with a recent decline of 1.16% over the last five trading days. Over the past 20 days, the stock has risen by 6.09%, while it has increased by 3.79% over the last 60 days [2]. - As of January 16, the stock was trading at 90.48 yuan per share, with a trading volume of 50.0166 million yuan and a turnover rate of 0.78% [1]. Group 2: Company Overview - Ruimait Medical Technology Co., Ltd. was established on July 27, 2001, and went public on November 1, 2022. The company specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector [2]. - The company's main business revenue composition includes home respiratory therapy products (64.19%), consumables (32.67%), medical products (3.05%), and others (0.10%) [2]. Group 3: Financial Performance - For the period from January to September 2025, Ruimait achieved an operating income of 808 million yuan, representing a year-on-year growth of 34.24%. The net profit attributable to shareholders was 180 million yuan, reflecting a year-on-year increase of 43.87% [3]. - Since its A-share listing, Ruimait has distributed a total of 228 million yuan in dividends [4]. Group 4: Shareholder Information - As of September 30, 2025, Ruimait had 7,971 shareholders, an increase of 16.36% from the previous period. The average number of circulating shares per person decreased by 14.20% to 7,080 shares [3]. - Among the top ten circulating shareholders, Huatai-PineBridge Healthcare Mixed Fund is the sixth largest, holding 1.2953 million shares as a new shareholder [4].

证券日报网讯 1月14日，瑞迈特在互动平台回答投资者提问时表示，上市公司股东人数属于应当在定期 报告中披露的信息。为确保信息披露的公平性及合规性，公司在非定期报告时点原则上不单独披露股东 人数变动信息，最新股东人数数据请以公司在中国证监会指定信息披露媒体发布的定期报告为准。根据 公司披露的2025年三季度报告，截至2025年9月30日，公司股东总户数为7971户。 登录新浪财经APP 搜索【信披】查看更多考评等级 （文章来源：证券日报） ...